Express Pharma
APRIL 16, 2024
As the world’s leading supplier of generic drugs, India’s pharmaceutical industry has become a ray of hope for millions as it ensures quality-assured and cost-effective treatments reach those who need them the most. It also contributes to 40 per cent of medications in the US and 33 per cent in the EU.
pharmaphorum
OCTOBER 17, 2022
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga ( TAK-003 ). Medicines submitted under EU-M4all are assessed by the CHMP in collaboration with the WHO and target countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 29, 2022
With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.
European Pharmaceutical Review
APRIL 25, 2024
Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally. Overall, increasing demand for generic medicines will be a significant factor for growth.
STAT
OCTOBER 10, 2023
The state’s biotech scene exploded in the mid-2010s and early in the pandemic as exuberant investors disregarded the high failure rate in drug development and bet on buzzy technologies such as gene editing and messenger RNA vaccines. And although many companies are making layoffs, others are expanding.
Express Pharma
FEBRUARY 14, 2024
. “If accepted, these IP provisions will have drastic consequences on access to medicines and the health of patients in India and beyond. Millions of lives depend on India putting people’s health first and being able to continue supplying generic medicines globally,” according to Dr Mantoo.
European Pharmaceutical Review
FEBRUARY 26, 2024
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines.
Expert insights. Personalized for you.
102 
Let's personalize your content